Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents
Significance
Currently, cisplatin, carboplatin, and oxaliplatin are the only platinum agents approved by the US Food and Drug Administration for use in therapeutic regimens. While effective in select cancers, their clinical utility remains limited by intrinsic or acquired resistance. This is attributed, in part, to poor drug tumor localization and uptake. Additionally, one of the more formidable mechanisms of platinum resistance involves dysfunction of the tumor suppressor p53. Lack of wild-type p53 activation can translate to a significant reduction in the 5-y survival rate compared with mutant p53 in some cancers. The inability to overcome p53 dysfunction in concert with the dose-limiting toxicities and poor tumor-specific drug delivery of Pt provides an incentive to develop agents as described in this report.
Citations by journals
1
2
3
|
|
Journal of Medicinal Chemistry
|
Journal of Medicinal Chemistry
3 publications, 7.32%
|
Coordination Chemistry Reviews
|
Coordination Chemistry Reviews
3 publications, 7.32%
|
Inorganic Chemistry Frontiers
|
Inorganic Chemistry Frontiers
3 publications, 7.32%
|
Chem
|
Chem
2 publications, 4.88%
|
Journal of the American Chemical Society
|
Journal of the American Chemical Society
2 publications, 4.88%
|
Chemical Society Reviews
|
Chemical Society Reviews
2 publications, 4.88%
|
Chemical Science
|
Chemical Science
2 publications, 4.88%
|
Dalton Transactions
|
Dalton Transactions
2 publications, 4.88%
|
ACS Applied Bio Materials
|
ACS Applied Bio Materials
1 publication, 2.44%
|
Bioscience Reports
|
Bioscience Reports
1 publication, 2.44%
|
Nature Communications
|
Nature Communications
1 publication, 2.44%
|
Communications Chemistry
|
Communications Chemistry
1 publication, 2.44%
|
Inorganic Chemistry
|
Inorganic Chemistry
1 publication, 2.44%
|
Journal of Controlled Release
|
Journal of Controlled Release
1 publication, 2.44%
|
Journal of Molecular Structure
|
Journal of Molecular Structure
1 publication, 2.44%
|
Current Opinion in Chemical Biology
|
Current Opinion in Chemical Biology
1 publication, 2.44%
|
Angewandte Chemie
|
Angewandte Chemie
1 publication, 2.44%
|
Angewandte Chemie - International Edition
|
Angewandte Chemie - International Edition
1 publication, 2.44%
|
ChemMedChem
|
ChemMedChem
1 publication, 2.44%
|
Chemistry - A European Journal
|
Chemistry - A European Journal
1 publication, 2.44%
|
Molecular Pharmaceutics
|
Molecular Pharmaceutics
1 publication, 2.44%
|
Chemical Communications
|
Chemical Communications
1 publication, 2.44%
|
Proceedings of the National Academy of Sciences of the United States of America
|
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 2.44%
|
Nanoscale
|
Nanoscale
1 publication, 2.44%
|
Science advances
|
Science advances
1 publication, 2.44%
|
ACS Sensors
|
ACS Sensors
1 publication, 2.44%
|
Advanced healthcare materials
|
Advanced healthcare materials
1 publication, 2.44%
|
Acta Pharmaceutica Sinica B
|
Acta Pharmaceutica Sinica B
1 publication, 2.44%
|
ACS Infectious Diseases
|
ACS Infectious Diseases
1 publication, 2.44%
|
1
2
3
|
Citations by publishers
2
4
6
8
10
12
|
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
11 publications, 26.83%
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
10 publications, 24.39%
|
Elsevier
|
Elsevier
9 publications, 21.95%
|
Wiley
|
Wiley
5 publications, 12.2%
|
Springer Nature
|
Springer Nature
3 publications, 7.32%
|
Proceedings of the National Academy of Sciences (PNAS)
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 2.44%
|
American Association for the Advancement of Science (AAAS)
|
American Association for the Advancement of Science (AAAS)
1 publication, 2.44%
|
2
4
6
8
10
12
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.